Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ:DSGN) with a Sell rating and a $10 price target. 

  • The analyst Madhu Kumar has caution about the Company's lead indication of Friedreich ataxia. 
  • Natural history studies provide little support that differences in FXN levels will shift the FA disease course. 
  • At the same time, high-dose nicotinamide has already achieved clinically meaningful FXN induction with the minimal observed change in clinical effect in FA patients, Kumar tells investors in a research note. 
  • He believes Design shares are "priced with little room for error."
  • In September, the Company posted new preclinical data from its novel DM1 GeneTAC program.
  • The data demonstrated DM1 GeneTAC's potential to potently and selectively block the mutant DMPK gene expression in DM1 patient cells. 
  • Reduction of nuclear foci was associated with clear correction of splicing defects involved in the multi-system pathophysiology of DM1.
  • Price Action: DSGN shares are down 4.85% at $14.13 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.